(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or ...
The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FRANKFURT (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose ...
Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the ...
Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve retention in crowded GLP-1 market. Millions of people on GLP-1 weight-loss ...
The new injector device is intended to allow adults to self-administer Acthar Gel with fewer steps. The Food and Drug Administration (FDA) has approved a new single-dose prefilled SelfJect ™ Injector ...
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results